CN104983755A - Application of pharmaceutical composition in preparation of drugs for treating osteoporosis - Google Patents
Application of pharmaceutical composition in preparation of drugs for treating osteoporosis Download PDFInfo
- Publication number
- CN104983755A CN104983755A CN201510438473.4A CN201510438473A CN104983755A CN 104983755 A CN104983755 A CN 104983755A CN 201510438473 A CN201510438473 A CN 201510438473A CN 104983755 A CN104983755 A CN 104983755A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- ginsenoside
- parts
- preparation
- osteoporosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention belongs to the technical field of traditional Chinese medicine, and relates to an application of a pharmaceutical composition in the preparation of drugs for treating osteoporosis. The pharmaceutical composition comprises the following raw materials: stilbene glucoside, ginsenoside Rb1, ginsenoside Rg1, ginsenoside Rd, ginsenoside Re, ginkgolide, kaempferol, and quercetin. The provided pharmaceutical composition has a scientific formula and strong synergetic effect, can be co-used with drugs for treating osteoporosis, and achieves a prominent effect, which has been proved in clinic.
Description
Technical field
The invention belongs to technical field of Chinese medicines, particularly relate to a kind of pharmaceutical composition for the preparation of the purposes in treatment medicine for treating osteoporosis.
Background technology
Osteoporosis is a kind of with bone amount minimizing, and the fine structure of bone destroys as feature, and the fragility causing bone increases, and is easy to a kind of general osteopathia of fracturing.Osteoporosis can be divided into three major types: primary osteoporosis, secondary osteoporosis and idiopathic osteoporosis.First kind primary osteoporosis can be divided into again osteoporosis (I type) and the senile osteoporosis (II type) of menopausal women; Equations of The Second Kind is secondary osteoporosis, and it is by other diseases (as renal failure, excess thyroid hormone or leukemia), or some factors such as medicine (as steroid) the osteoporosis of being brought out; 3rd class is idiopathic osteoporosis, and be more common in teenager or the adult in 8-14 year, mostly have hereditary family history, women is more than male, and the osteoporosis that forepart pregnant women and age of sucking occur also can list idiopathic osteoporosis in.
Chinese invention patent 200810198306 discloses a kind of compositions of the Effective Component of Chinese Medicine for preventing and treating diseased associated with cerebral ischemia injury, but openly not may be used for treating other diseases.
Chinese patent application 201410797516.3 discloses a kind of medicine being used for the treatment of osteoporosis, and this Chinese medicine composition is obtained by following raw material: Ramulus et Folium Psychotriae Serpentis 24-48 part, Carnis Coturnicis japonicae 22-47 part, Radix calophylli membranacei 20-44 part, Radix seu Caulis Verntilaginis Leiocarpae 20-44 part, Herba Thesii 17-42 part, Mytilus 16-40 part, Herba Sambuci Adnatae 16-40 part, Radix Flemingiae Philippinensis 15-35 part, Parmelia saxatilis Ach. 15-35 part, Herba Hoyae lancilimbae 14-32 part, Radix Angelicae Sinensis 14-32 part, Caulis Piperis Boehmeriaefolii 12-30 part.This Chinese medicine composition has keeps fit effect of strong bone, blood yiqi, but this traditional Chinese medicine composite not easily obtains, and preparation technology is more complicated, is unfavorable for batch, produces fast.
Chinese patent application 200910230776.1 discloses a kind of Chinese medicine composition for the treatment of osteoporosis, this Chinese medicine composition is obtained by following raw material: Herba Epimedii 15-20g, Cortex Eucommiae 10-15g, Radix Notoginseng 5-10g, Radix Astragali 10-15g, Ramulus Cinnamomi 10-15g, Rhizoma Chuanxiong 5-10g, Radix Rehmanniae Preparata 5-10g, Radix Angelicae Sinensis 10-15g, Rhizoma Drynariae 10-15g, Radix Angelicae Dahuricae 10-15g.It is simple, reasonable that this Chinese medicine composition has preparation, the advantages such as good effect, but strengthening the tendons and bones, blood nourishing and calcium replenishing aspect effect are not very remarkable.
Summary of the invention
The technical problem to be solved in the present invention is to provide a kind of pharmaceutical composition for the preparation of the purposes in treatment medicine for treating osteoporosis, this pharmaceutical composition has effect of invigorating the kidney and strengthening the bones, blood circulation promoting and blood stasis dispelling and replenishing QI to invigorate the spleen, also there is good effect, cost is low, preparation technology is simple, the advantages such as cure rate is high, taking convenience.Described pharmaceutical composition can utilize modern pharmaceutical technology to make to facilitate easy-to-use finished product preparation.
Prove through the test of pesticide effectiveness, pharmaceutical composition of the present invention can also treat osteoporosis, and therapeutic effect is obvious, toxic and side effects is little, the therapeutic effect persistent period is long, slow down the misery of patients with osteoporosis greatly, significantly improve the compliance of sufferers of osteoporosis face, and improve the quality of life of patient.
This pharmaceutical composition comprises the raw materials of following parts by weight: stilbene glucoside 1-18 part, ginsenoside Rb1 1-10 part, ginsenoside Rg1 1-10 part, ginsenoside Rd 1-2 part, ginsenoside Re 1-4 part, bilobalide 1-4 part, kaempferol 1-2 part, Quercetin 1-2 part.
Preferably, described pharmaceutical composition comprises the raw materials of following parts by weight: stilbene glucoside 1 part, ginsenoside Rb1 1 part, ginsenoside Rg1 1 part, ginsenoside Rd 1 part, ginsenoside Re 1 part, bilobalide 1 part, kaempferol 1 part and Quercetin 1 part.
Preferably, described pharmaceutical composition comprises the raw materials of following parts by weight: stilbene glucoside 18 parts, ginsenoside Rb1 10 parts, ginsenoside Rg1 10 parts, ginsenoside Rd 2 parts, ginsenoside Re 4 parts, bilobalide 4 parts, kaempferol 2 parts and Quercetin 2 parts.
Preferably, described pharmaceutical composition comprises the raw materials of following parts by weight: stilbene glucoside 10 parts, ginsenoside Rb1 5 parts, ginsenoside Rg1 5 parts, ginsenoside Rd 1.5 parts, ginsenoside Re 2 parts, bilobalide 2 parts, kaempferol 1.5 parts and Quercetin 1.5 parts.
Preferably, described pharmaceutical composition is made into capsule, tablet, granule or pill.
Accordingly, the preparation technology of pharmaceutical composition of the present invention comprises the following steps:
Take raw material, add the water of initial feed 8-12 times of weight, soak 12-24 hour, backflow decocts 1-3 hour, filters, then adds the water of initial feed 3-6 times of weight, backflow decocts 1-3 hour, filter, obtain filtrate, merging filtrate, being concentrated into 50 DEG C of-60 DEG C of relative densities is the Chinese medical concrete of 1.25-1.35, dry, pulverize into fine powder, obtain pharmaceutical composition.
Effect of the present invention's component used:
Stilbene glucoside: this product is one of main component of Polygonaceae arsesmart Radix Polygoni Multiflori is a kind of Polyhydroxy phenol; Radix Polygoni Multiflori has obvious invigorating the liver and kidney, benefiting essence-blood, bone and muscle strengthening, black hair, calms the nerves, stops the effects such as juice; Stilbene glucoside active component in Radix Polygoni Multiflori has and reduces blood fat significantly, protects the liver effects such as protecting kidney.
Ginsenoside Rb1: this product is the dry root of Araliaceae Radix Ginseng; The effects such as Radix Ginseng has strongly invigorating primordial QI, strengthening by means of tonics, and Fructus Alpiniae Oxyphyllae of calming the nerves, promotes the production of body fluid, and multiple arteries and veins is admittedly de-; Research shows, ginsenoside Rb1 has protective effect to rat acute injury of renal tubular, and can promote that rabbit cartilage cell is bred.
Ginsenoside Rg1: this product is the dry root for Araliaceae Radix Ginseng; Radix Ginseng, by increasing the synthesis of bone marrow DNA, RNA, protein and lipid, promotes medullary cell mitosis, has the function of hemopoietic; Ginsenoside Rg1 has the function promoting hemopoietic, also has the function of vital energy benefiting and the kidney invigorating.
Ginsenoside Rd: this product is the dry root for Araliaceae Radix Ginseng; There is strongly invigorating primordial QI, effect of strengthening by means of tonics.
Ginsenoside Re: this product is the dry root for Araliaceae Radix Ginseng; Its molecular formula is C
48h
82o
18, molecular weight is 947.14, has effect of the kidney invigorating benefit blood.
Bilobalide: this product is the important active component of Semen Ginkgo Ye Zhongyi class; There is blood circulation promoting and blood stasis dispelling, effect of removing obstruction in the collateral to relieve pain.
Kaempferol: this product derives from zingiberaceous plant Rhizoma Kaempferiae rhizome, has temperature compensation kidney spleen, effect of antiphlogistic antibacterial.
Quercetin: this product plants source property flavone compound in the plants such as fruit, vegetable and corn at a kind of being present in, and has stomach reinforcing of enriching blood, effect of antiinflammatory hepatoprotective.
Found the impact of rat bone density experiment by pharmaceutical composition of the present invention, pharmaceutical composition of the present invention has and improves osteoporosis, improves effect of bone density.This experiment adopts QIANGGU JIAONANG as a control group, the main component of QIANGGU JIAONANG comprises Process of Total Flavonoids in Drynaria Fortunei, there is effect of the kidney invigorating, bone strengthening, strong muscle, pain relieving, be used for the treatment of the Kidney-Yang Deficiency Syndrome of primary osteoporosis, bone amount minimizing patient, by treating comparing of the therapeutic effect in osteoporosis with pharmaceutical composition of the present invention, embodying the curative effect of pharmaceutical composition of the present invention in treatment osteoporosis.In addition, to rat oral gavage retinoic acid, retinoic acid is the growth of the metabolic intermediate of vitamin A in human body, major effect bone, passes through injectable drug, and measure the bone density of rat, can find out medicine for treatment osteoporosis rat effect, another inventor surprisingly, the femur volume of the rat of basic, normal, high dosage group is compared with model group, have the difference of remarkable shape, femur dry weight, ash weight, bone calcium and bone density then have extremely significant difference compared with model group; In addition, model group, compared with blank group, all has the difference of significance in femur volume, dry weight, ash weight, bone calcium and bone density; In addition, the femur volume of the rat of BUSHEN JIANGU JIAONANG matched group and basic, normal, high dosage group, dry weight, ash is heavy, bone calcium is suitable with bone density.Visible, the rat bone loss that pharmaceutical composition of the present invention can obviously suppress retinoic acid to cause, improves osteoporosis, improves bone density.
Found the clinical observation on the therapeutic effect of osteoporosis clinical volunteers patient by pharmaceutical composition of the present invention, pharmaceutical composition of the present invention has good effect, obvious effective rate advantages of higher.The patient of this clinical trial is the patient in 19-79 year, because osteoporosis can occur in all age group, so the larger patient of the range of choice is as subjects, at present, the drug main for the treatment of osteoporosis will comprise calcium preparation, chemical drugs and Chinese patent medicine, this test adopts BUSHEN JIANGU JIAONANG as a control group, the main component of BUSHEN JIANGU JIAONANG comprises Radix Rehmanniae Preparata, Fructus Corni, Rhizoma Dioscoreae, Rhizoma Cibotii, Herba Epimedii, Radix Angelicae Sinensis, Rhizoma Alismatis, Cortex Moutan, Poria and Concha Ostreae, there is nourishing the liver and kidney, effect of strengthening the tendons and bones, for the symptom such as deficiency of the liver and kindey of primary osteoporosis, by comparing with medicine composite for curing effect of the present invention, embody the curative effect of pharmaceutical composition of the present invention in treatment osteoporosis, make inventor surprisingly, the obvious effective rate of pharmaceutical composition of the present invention is 84.2%, total effective rate is 93.3%, far above the obvious effective rate of matched group 56.7% and the total effective rate of 75.8%, visible, pharmaceutical composition good effect of the present invention, obvious effective rate is high, can as the drug use for the treatment of osteoporosis.
Compared with prior art, the present invention has following technical advantage:
1, pharmaceutical composition of the present invention is in treatment osteoporosis, and have increase bone density, the effect of bone calcium, the patient of each age group all can use;
2, pharmaceutical composition of the present invention is natural pure Chinese medicinal preparation, and toxic and side effects is little;
3, pharmaceutical composition of the present invention has effect of invigorating the kidney and strengthening the bones, blood circulation promoting and blood stasis dispelling and replenishing QI to invigorate the spleen, also has good effect, and cost is low, and preparation technology is simple, the advantages such as obvious effective rate is high, taking convenience.
Detailed description of the invention
It will be understood by those skilled in the art that technology disclosed in following examples represents the technology playing good action in the practice of the invention of the present inventor's discovery.But, many changes can be made in disclosed specific embodiments, and still obtain same or analogous result, and not depart from the spirit and scope of the present invention.
part I drug combination preparation of the present invention and preparation method thereof
the agent of embodiment 1-5 medicament composition granule
Table 1 medicament composition granule agent prescription of the present invention
Embodiment 1 preparation method:
Take raw material, add the water of initial feed 12 times of weight, soak 24 hours, backflow decoction 3 hours, filters, then adds the water of initial feed 6 times of weight, backflow decoction 3 hours, filters, obtains filtrate, merging filtrate, being concentrated into 60 DEG C of relative densities is the Chinese medical concrete of 1.30, dry, grind to form powdery, add starch, 5% gelatin solution and distilled water, be pressed into thin slice, be ground into granule, obtain the granule of pharmaceutical composition.Embodiment 2-5 preparation method is with embodiment 1.
the agent of embodiment 6-10 medicament composition capsule
Table 2 medicament composition capsule agent prescription of the present invention
Embodiment 6 preparation method:
Take raw material, add the water of initial feed 12 times of weight, soak 24 hours, backflow decoction 3 hours, filters, then adds the water of initial feed 6 times of weight, backflow decoction 3 hours, filters, obtains filtrate, merging filtrate, being concentrated into 60 DEG C of relative densities is the Chinese medical concrete of 1.30, add starch, lactose, 5% gelatin solution, dried starch and distilled water, mixing, dry, pulverize into fine powder, incapsulate in shell, obtain the capsule preparations of pharmaceutical composition.Embodiment 7-10 preparation method is with embodiment 6.
embodiment 11-15 medicinal composition tablets
Table 3 medicinal composition tablets formula of the present invention
Embodiment 11 preparation method:
Take raw material, add the water of initial feed 12 times of weight, soak 24 hours, backflow decoction 3 hours, filters, then adds the water of initial feed 6 times of weight, backflow decoction 3 hours, filters, obtains filtrate, merging filtrate, being concentrated into 60 DEG C of relative densities is the Chinese medical concrete of 1.30, drying under reduced pressure, be ground into fine powder, add starch, lactose, 20% gelatin solution, dried starch and distilled water, add lubricant after combination drying, tabletting, coating, obtains the tablet of pharmaceutical composition.Embodiment 12-15 preparation method is with embodiment 11.
part II pharmaceutical composition pharmacodynamic study of the present invention
pharmaceutical composition of the present invention is tested the impact of rat bone density
1 experiment material:
(1) laboratory animal: SD rat, 0.15kg-0.3kg, male and female half and half, are provided by Zhongshan University's Experimental Animal Center.
(2) Experimental agents: the medicament composition capsule agent that the embodiment of the present invention 10 prepares; QIANGGU JIAONANG (Beijing Chinese medicine pharmaceutical Co. Ltd, accurate word Z20030007, the 0.25*30 grain/bottle of traditional Chinese medicines).
(3) experimental apparatus: UMSP-30 type microscope spectrophotometer, VIDAS Image analysis system.
2 experimental techniques:
Get SD rat 60, be divided into 6 groups at random, often organize 10, be respectively blank group, model group (isometric(al) normal saline), low dose group (0.38g/kg ﹒ d), middle dosage group (1.14 g/kg ﹒ d), high dose group (2.28g/kg ﹒ d) and QIANGGU JIAONANG matched group (0.9 g/kg ﹒ d); Except blank group, the retinoic acid of rats difference gavage 0.06g/kg that every day is respectively organized to other, stop using after two weeks, and the simultaneously corresponding medicine of gavage, blank group and model group be gavage isometric(al) normal saline then, continuous use surrounding (retinoic acid stop using after, continue medication two weeks), after surrounding, by rat sacrificed by decapitation, take a blood sample, get bone, under fluorescence irradiates, with microscope spectrophotometer, tibia sectioning image is all inputted Image analysis system, in computer, carry out data and image procossing.
3 experimental results
Table 1 respectively group rat femur meterological change
Note: compare with blank group,
△p ﹤ 0.05,
△ △p ﹤ 0.01; Compare with model group,
▲p ﹤ 0.05,
▲ ▲p ﹤ 0.01.
4 conclusions
This experiment adopts QIANGGU JIAONANG as a control group, the main component of QIANGGU JIAONANG comprises Process of Total Flavonoids in Drynaria Fortunei, there is effect of the kidney invigorating, bone strengthening, strong muscle, pain relieving, be used for the treatment of the Kidney-Yang Deficiency Syndrome of primary osteoporosis, bone amount minimizing patient, by treating comparing of the therapeutic effect in osteoporosis with pharmaceutical composition of the present invention, embodying the curative effect of pharmaceutical composition of the present invention in treatment osteoporosis.In addition, to rat oral gavage retinoic acid, retinoic acid is the growth of the metabolic intermediate of vitamin A in human body, major effect bone, passes through injectable drug, and measure the bone density of rat, can find out medicine for treatment osteoporosis rat effect, another inventor surprisingly, the femur volume of the rat of basic, normal, high dosage group is compared with model group, have the difference of remarkable shape, femur dry weight, ash weight, bone calcium and bone density then have extremely significant difference compared with model group; In addition, model group, compared with blank group, all has the difference of significance in femur volume, dry weight, ash weight, bone calcium and bone density; In addition, the femur volume of the rat of BUSHEN JIANGU JIAONANG matched group and basic, normal, high dosage group, dry weight, ash is heavy, bone calcium is suitable with bone density.Visible, the rat bone loss that pharmaceutical composition of the present invention can obviously suppress retinoic acid to cause, improves osteoporosis, improves bone density.
pharmaceutical composition of the present invention is to the clinical observation on the therapeutic effect of osteoporosis clinical volunteers patient
(1) case and diagnostic criteria
1, Western medicine diagnose standard:
With reference to " Chinese's osteoporosis suggestion diagnostic criteria " (the second original text) and " new Chinese medicine guideline of clinical investigations ", determining that the diagnostic criteria of this test is as follows: possess overall pain, is main mainly with lumbar and back pain, aching and limp unable, increase the weight of gradually, microtrauma can cause fracture; Scheuermann kyphosis deformity; Bone density reduces by 2 above persons of standard deviation.
Note: (1) bone density refers to measures the meansigma methods of lumbar vertebra 2-4 vertebral bone density or the bone density value of hip with Dual-energy X-rays absorptionmetry (DEXA), as long as one of them reaches lower than 2 above persons of standard deviation;
(2) pain is modal, the topmost symptom of osteoporosis.Clinical the most common with lumbago and backache, for spinous process or have tenderness and percussion pain, with whole body skeleton pain;
(3) be suitable for lumbar vertebra by the diagnostic index that standard deviation represents, hip position can refer to execution.When standard deviation inconvenience application, available lumbar vertebra Percentage of bone loss (%) diagnostic index.
2, tcm diagnosis standard:
Evaluation with reference to " guideline of clinical investigations of new Chinese medicine treatment osteoporosis " of " new Chinese medicine guideline of clinical investigations " (2002) requires to formulate.Diagnostic criteria is: lumbar vertebrae pain, aching and limp few power, walk with difficulty, the vertigo, can not be prudent, body of the tongue or partially red or light, thin lingual fur or thin white, deep-thready pulse etc.
3, Excluded cases standard: 1) have secondary osteoporosis and other serious complication persons such as hyperparathyroidism, osteomalacia, rheumatoid arthritis, multiple myeloma; Or late deformity, maimed person, disability person; 2) severe primary such as cardiovascular and hemopoietic system disease patient is associated with; 3) liver function ALT is more than 1.5 times of upper limits of normal; Renal function serum creatinine > 133umol/L; 4) psychosis or old dementia patients; 5) adopt hormone replacement therapy (HRT) in nearly three months and take calcitonin (as Calcitonin and elcatonin), having continuous 15 days in nearly six months and apply Diphosphonate person.
Two, clinical trial
1 physical data
Clinical volunteers patient of all selected fracture being loosened is divided into two groups at random, treatment group 120 example, wherein male patient 78 example, female patient 42 example; Matched group 120 example, wherein male patient 65 example, female patient 55 example.Age is 19 years old-79 years old, 49 years old mean age.Two groups of influence factors such as age, symptom, through statistical procedures, there was no significant difference, meets a point set condition.
2 Therapeutic Method
Treatment group: take the capsule (0.3g*100 grain/bottle) that embodiment 10 prepares, every day 3 times, each 4, serve on 3 months;
Matched group: take BUSHEN JIANGU JIAONANG (Wuhan JianMin Pharmaceutical Group Co., Ltd, accurate word Z20020056, the 0.58g*36 grain/box of traditional Chinese medicines), each 4,3 times on the one, serve on 3 months.
3 evaluation of clinical curative effect standards
Osteoporosis bone density efficacy determination
Effective: bone density rate of change is more than or equal to the minimum significant change value of bone density;
Effective: bone density rate of change is between the minimum significant change value of positive and negative bone density;
Invalid: bone density rate of change is less than the minimum significant change value of negative bone density.
The wherein minimum significant change value of bone density
4 therapeutic outcomes, as shown in table 2.
Table 2 therapeutic effect
5 conclusions
The patient of this clinical trial is the patient in 19-79 year, because osteoporosis can occur in all age group, so the larger patient of the range of choice is as subjects, at present, the drug main for the treatment of osteoporosis will comprise calcium preparation, chemical drugs and Chinese patent medicine, this test adopts BUSHEN JIANGU JIAONANG as a control group, the main component of BUSHEN JIANGU JIAONANG comprises Radix Rehmanniae Preparata, Fructus Corni, Rhizoma Dioscoreae, Rhizoma Cibotii, Herba Epimedii, Radix Angelicae Sinensis, Rhizoma Alismatis, Cortex Moutan, Poria and Concha Ostreae, there is nourishing the liver and kidney, effect of strengthening the tendons and bones, for the symptom such as deficiency of the liver and kindey of primary osteoporosis, by comparing with medicine composite for curing effect of the present invention, embody the curative effect of pharmaceutical composition of the present invention in treatment osteoporosis, make inventor surprisingly, the obvious effective rate of pharmaceutical composition of the present invention is 84.2%, total effective rate is 93.3%, far above the obvious effective rate of matched group 56.7% and the total effective rate of 75.8%, visible, pharmaceutical composition good effect of the present invention, obvious effective rate is high, can as the drug use for the treatment of osteoporosis.
Owing to describing the present invention by above preferred embodiment, in spirit of the present invention and/or scope, any for replacement/of the present invention or combination implement the present invention, be all apparent for a person skilled in the art, and be included among the present invention.
Claims (6)
1. a pharmaceutical composition is for the preparation of the purposes in treatment medicine for treating osteoporosis, it is characterized in that, described pharmaceutical composition is obtained by the raw material of following weight portion: stilbene glucoside 1-18 part, ginsenoside Rb1 1-10 part, ginsenoside Rg1 1-10 part, ginsenoside Rd 1-2 part, ginsenoside Re 1-4 part, bilobalide 1-4 part, kaempferol 1-2 part, Quercetin 1-2 part.
2. a kind of pharmaceutical composition according to claim 1 is for the preparation of the purposes in treatment medicine for treating osteoporosis, it is characterized in that, described pharmaceutical composition is obtained by the raw material of following weight portion: stilbene glucoside 1 part, ginsenoside Rb1 1 part, ginsenoside Rg1 1 part, ginsenoside Rd 1 part, ginsenoside Re 1 part, bilobalide 1 part, kaempferol 1 part and Quercetin 1 part.
3. a kind of pharmaceutical composition according to claim 1 is for the preparation of the purposes in treatment medicine for treating osteoporosis, it is characterized in that, described pharmaceutical composition is obtained by the raw material of following weight portion: stilbene glucoside 18 parts, ginsenoside Rb1 10 parts, ginsenoside Rg1 10 parts, ginsenoside Rd 2 parts, ginsenoside Re 4 parts, bilobalide 4 parts, kaempferol 2 parts and Quercetin 2 parts.
4. a kind of pharmaceutical composition according to claim 1 is for the preparation of the purposes in treatment medicine for treating osteoporosis, it is characterized in that, described pharmaceutical composition is obtained by the raw material of following weight portion: stilbene glucoside 10 parts, ginsenoside Rb1 5 parts, ginsenoside Rg1 5 parts, ginsenoside Rd 1.5 parts, ginsenoside Re 2 parts, bilobalide 2 parts, kaempferol 1.5 parts and Quercetin 1.5 parts.
5. according to the arbitrary described a kind of pharmaceutical composition of claim 1-4 for the preparation of the purposes in treatment medicine for treating osteoporosis, it is characterized in that: described pharmaceutical composition can be made into capsule, tablet, granule or pill.
6. according to the arbitrary described a kind of pharmaceutical composition of claim 1-4 for the preparation of the purposes in treatment medicine for treating osteoporosis, it is characterized in that, the preparation method of described pharmaceutical composition comprises the following steps: take raw material, add the water of initial feed 8-12 times of weight, soak 12-24 hour, backflow decocts 1-3 hour, filter, add the water of initial feed 3-6 times of weight again, backflow decocts 1-3 hour, filter, obtain filtrate, merging filtrate, being concentrated into 50 DEG C of-60 DEG C of relative densities is the Chinese medical concrete of 1.25-1.35, dry, be ground into fine powder, obtain pharmaceutical composition.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510438473.4A CN104983755A (en) | 2015-07-24 | 2015-07-24 | Application of pharmaceutical composition in preparation of drugs for treating osteoporosis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510438473.4A CN104983755A (en) | 2015-07-24 | 2015-07-24 | Application of pharmaceutical composition in preparation of drugs for treating osteoporosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104983755A true CN104983755A (en) | 2015-10-21 |
Family
ID=54295744
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510438473.4A Withdrawn CN104983755A (en) | 2015-07-24 | 2015-07-24 | Application of pharmaceutical composition in preparation of drugs for treating osteoporosis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104983755A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105168272A (en) * | 2015-09-29 | 2015-12-23 | 罗奕珺 | Application of pharmaceutical composition to preparation of drug for treating osteoporosis |
| CN106389493A (en) * | 2016-10-12 | 2017-02-15 | 王璐林 | Drug for treating osteonecrosis and promoting bone repair |
| KR101856477B1 (en) | 2017-06-05 | 2018-05-14 | 대한민국 | Composition comprising complex of ginsenodise as an effective ingredient for preventing or treating of bone disease |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1709274A (en) * | 2005-06-08 | 2005-12-21 | 广东医学院 | Novel use of medicinal formulation capable of improving cerebral metabolism for preventing and treating osteoporosis |
| CN101646433A (en) * | 2006-10-24 | 2010-02-10 | 戴维·W·克雷姆平 | Anti-resorbent and make the dietary supplement and the using method of bone |
| CN101647846A (en) * | 2008-08-12 | 2010-02-17 | 羊敏 | Tibet medicament for treating pneumoconiosis and preparation method thereof |
| CN102283877A (en) * | 2011-07-26 | 2011-12-21 | 上海市中医医院 | Application of ginsenoside |
| CN102784155A (en) * | 2012-05-23 | 2012-11-21 | 中国人民解放军第四军医大学 | Application of stilbeneglycoside to prophylaxis and treatment of osteoporosis |
-
2015
- 2015-07-24 CN CN201510438473.4A patent/CN104983755A/en not_active Withdrawn
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1709274A (en) * | 2005-06-08 | 2005-12-21 | 广东医学院 | Novel use of medicinal formulation capable of improving cerebral metabolism for preventing and treating osteoporosis |
| CN101646433A (en) * | 2006-10-24 | 2010-02-10 | 戴维·W·克雷姆平 | Anti-resorbent and make the dietary supplement and the using method of bone |
| CN101647846A (en) * | 2008-08-12 | 2010-02-17 | 羊敏 | Tibet medicament for treating pneumoconiosis and preparation method thereof |
| CN102283877A (en) * | 2011-07-26 | 2011-12-21 | 上海市中医医院 | Application of ginsenoside |
| CN102784155A (en) * | 2012-05-23 | 2012-11-21 | 中国人民解放军第四军医大学 | Application of stilbeneglycoside to prophylaxis and treatment of osteoporosis |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105168272A (en) * | 2015-09-29 | 2015-12-23 | 罗奕珺 | Application of pharmaceutical composition to preparation of drug for treating osteoporosis |
| CN106389493A (en) * | 2016-10-12 | 2017-02-15 | 王璐林 | Drug for treating osteonecrosis and promoting bone repair |
| KR101856477B1 (en) | 2017-06-05 | 2018-05-14 | 대한민국 | Composition comprising complex of ginsenodise as an effective ingredient for preventing or treating of bone disease |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104547486A (en) | Traditional Chinese medicine preparation for treating anemia and qi-deficiency weakness and preparation process for traditional Chinese medicine preparation | |
| CN104983755A (en) | Application of pharmaceutical composition in preparation of drugs for treating osteoporosis | |
| CN101703662B (en) | Oral Chinese medicament for treating hyperosteogeny | |
| CN104887747A (en) | Traditional Chinese medicine composition for treating cerebral thrombosis and preparation method therefor | |
| CN101138597B (en) | Traditional Chinese medicine preparation for preventing and controlling osteoporosis and method of preparing the same | |
| CN102133317B (en) | Medicament for treating fracture and preparation method thereof | |
| CN104491733A (en) | Application of traditional Chinese medicine preparation in preparation of medicines for treating anemia, deficiency of vital energy and debilitation | |
| CN103948791A (en) | Traditional Chinese medicinal composition for reducing blood fat, and preparation method thereof | |
| CN105287658A (en) | Application of medicine composition for preparing medicine for treating osteoporosis | |
| CN103142841B (en) | Traditional Chinese medicine composition for treating osteonecrosis of femoral head | |
| DE102004014005A1 (en) | Pharmaceutical composition for the prophylaxis or treatment of osteoporosis and process for its preparation | |
| CN104645080A (en) | Traditional Chinese medicine preparation for treating dizziness and preparation method of traditional Chinese medicine preparation | |
| CN105327121A (en) | Traditional Chinese medicine composition for treating female postmenopausal osteoporosis and preparing method thereof | |
| CN105012507A (en) | Traditional Chinese medicine composition for treating osteoporosis and preparation method of traditional Chinese medicine composition | |
| CN105311094A (en) | Application of pharmaceutical composition containing folium artemisiae argyi in preparing medicine for treating osteoporosis | |
| CN105168272A (en) | Application of pharmaceutical composition to preparation of drug for treating osteoporosis | |
| CN105232634A (en) | Application of pharmaceutical composition for preparing osteoporosis treating drug | |
| CN105250384A (en) | Application of pharmaceutical composition in preparation of drug for treating osteoporosis | |
| CN105456657A (en) | Traditional Chinese medicine composition for treating female postmenopausal osteoporosis and preparation method of traditional Chinese medicine composition | |
| CN108888736B (en) | External-use bone reunion medicine and preparation method thereof | |
| CN1205989C (en) | Medicine composition for treating ischemic necrosis of femur head and preparing process thereof | |
| CN105055816A (en) | Traditional Chinese medicine composite for treating cerebral thrombosis and preparation method thereof | |
| CN105267413A (en) | Traditional Chinese medicine composition for treating osteoporosis and preparation method thereof | |
| CN105797068A (en) | Application of traditional Chinese medicine preparation in preparation of medicine for treating heel pains through external application | |
| CN104940561A (en) | Traditional Chinese medicine preparation for treating eye diseases and preparing method of traditional Chinese medicine preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB03 | Change of inventor or designer information |
Inventor after: Bao Tongwen Inventor after: Bao Huailai Inventor after: Liu Changsheng Inventor before: Ding Feng |
|
| CB03 | Change of inventor or designer information | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20151021 |
|
| WW01 | Invention patent application withdrawn after publication |